Jeronselvein to Hold "PDRN Hands-On Course"... Expanding Clinical Applications in Dental Regenerative Medicine

Jeronselvein, a company specializing in the production of prescription drugs, announced on September 8 that it will hold a "PDRN Hands-On Course" seminar on September 14 in the seminar room on the first floor of the Megagen Tower.

The event is designed to share the clinical applications of Jeronselvein's core ingredient, polydeoxyribonucleotide (PDRN), as well as the latest regenerative medicine technologies and clinical experiences with dental professionals.

During the seminar, Lim Jongwon, Director of Best Dental Clinic, will begin by introducing "Clinical Cases of PDRN in Dentistry." Seol Wonseok, Director of Apple Dental Clinic, will present on "CASE You Can Do Too! Maximum Effect with Minimal Equipment." Yoon Jongil, Director of Yeon Dental Clinic, will deliver a lecture titled "Understanding PDRN and Its Clinical Use in Dentistry, and Bone Immunology," divided into Parts 1 and 2.

Next, Lee Deokwon, Director of The One Oral & Maxillofacial Surgery, will explain "MRONJ Injection Therapy Using PDRN," and Kim Hyungjun, Director of OFP Oral Medicine & Dentistry, will lecture on "Pathophysiology of Temporomandibular Disorders and PDRN Injection Therapy." Kwon Yongdae, Professor at Kyung Hee University Dental Hospital, will discuss "PDRN Pressure Lift for Transcrestal Approach," and Lee Sunjeong, Director of Yonsei SK Dental Clinic, is scheduled to share insights on "The Beginning of Dental Aesthetics: Utilizing PDRN."

Yoon Jongil, Vice President of the PDRN Immunoregenerative Dental Research Society and Director of Yeon Dental Clinic, stated, "PDRN is gaining attention as a next-generation ingredient for its outstanding regenerative effects. This seminar will provide practical clinical value to medical professionals through lectures combining theory and hands-on practice. We will continue to expand evidence-based educational programs to strengthen our expertise and credibility in the global regenerative medicine market."

Kim Deokgyu, CEO of Jeronselvein, said, "PDRN is recognized for its high potential in tissue regeneration, and its use in the dental field is rapidly increasing. Through this hands-on course, we hope that medical professionals will gain practical know-how that can be directly applied to patient care."

This content was produced with the assistance of AI translation services.